Invasive Pneumococcal Disease in New Zealand, 2010

More documents

Recommendations

Info

Appendix 10.Appendix 11.Appendix 12.Appendix 13.Appendix 14.Appendix 15.Penicillin and cefotaxime MIC distribution of pneumococci from invasivedisease, 2010 ................................................................................................... 36Trends in penicillin resistance, cefotaxime resistance and multidrug resistanceamong pneumococci from invasive disease, 2001-2010 ................................. 37Trends in resistance to non-β-lactam antibiotics, among pneumococci frominvasive disease, 2001-2010 ............................................................................ 38Penicillin and cefotaxime resistance among isolates from invasivepneumococcal disease by region and district health board (DHB), 2010 ....... 39Serotypes among penicillin resistant, cefotaxime resistant and intermediate,and multiresistant isolates from invasive pneumococcal disease cases, 2010 40Trends in penicillin resistance, cefotaxime resistance and multidrug resistanceamong serotype 19A pneumococci from invasive disease, 2001-2010 .......... 41Invasive pneumococcal disease September 2011in NZ, 2010
SUMMARYA 4-dose schedule of the 7-valent pneumococcal conjugate vaccine (PCV-7), Prevenar®, wasadded to the New Zealand childhood immunisation schedule in June 2008, with a catch-upprogramme for all children born on or after 1 January 2008. Since 17 October 2008, invasivepneumococcal disease (IPD) has been notifiable to medical officers of health under theHealth Act 1956.In this report, the data presented for 2009 and 2010 is based on IPD case notificationssupplemented with serotype and antimicrobial susceptibility data from ESR‟s nationallaboratory-based surveillance of invasive Streptococcus pneumoniae isolates. Data for earlieryears is solely from ESR‟s laboratory-based surveillance. For this laboratory-basedsurveillance, diagnostic microbiology laboratories are requested to refer all invasive isolatesof S. pneumoniae to ESR for serotyping and antimicrobial susceptibility testing.There were 535 cases of IPD notified in 2010, which equates to a rate of 12.2 cases per100 000. A S. pneumoniae isolate from an invasive site was received at ESR for serotypingand susceptibility testing for 514 (96.1%) of the notified cases.The incidence of IPD in infants
Page 1 and 2: INVASIVE PNEUMOCOCCAL DISEASEIN NEW
Page 3 and 4: DISCLAIMERThis report or document (
Page 5: CONTENTSSUMMARY ...................
Page 9 and 10: 1. INTRODUCTIONPrior to 2009, the n
Page 11 and 12: Data analyses were performed with S
Page 13 and 14: 3. RESULTSIn 2010, 535 IPD cases we
Page 15 and 16: The all-age rate of IPD in 2010 (12
Page 17: 3.4 Disease incidence by ethnicityT
Page 20 and 21: 3.7 Risk factors among IPD casesThe
Page 23 and 24: 3.10 Serotype distributionTable 9.
Page 25 and 26: Rate per 100 000The rate of disease
Page 27 and 28: 3.11 Antimicrobial susceptibilityTa
Page 29 and 30: Percent of penicillin-resistant iso
Page 31 and 32: type most frequently reported to ha
Page 33 and 34: REFERENCES1 Green MJ, Cawley PFM. I
Page 35 and 36: Appendix 1. Laboratory criteria upo
Page 37 and 38: Appendix 3. Rates of invasive pneum
Page 39 and 40: Appendix 5.2010Risk factors among i
Page 41 and 42: Appendix 7. Serotypes among invasiv
Page 43 and 44: Appendix 9. Serotype 1 invasive pne
Page 45 and 46: Appendix 11. Trends in penicillin r
Page 47 and 48: Appendix 13. Penicillin and cefotax
Page 49: Appendix 15. Trends in penicillin r

Invasive Pneumococcal Disease in New Zealand, 2010

You also want an ePaper? Increase the reach of your titles

Delete template?

Save as template?